Role of Shubhdeep Swasha Hara Pill in management of Shwasa roga (Asthma)

A Clinical Study To Evaluate The Therapeutic Effect Of Shubhdeep Swasha Hara Pill In The Management Of Tamaka Shwasa W.S.R. to Bronchial Asthma

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/01/022961

Enrollment

Registered

2020-01-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: SHUBHDEEP SWASHA HARA PILL: 500 mg BID with lukewarm water Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients presenting with clinical features of Bronchial Asthma 2)Patients aged between 16-70 years with irrespective of gender 3)Peak Expiratory flow Rate more than 80 Lit/min & less than 300 Lit/min.

Exclusion criteria

Exclusion criteria: 1)Patient aged less than 16 yr and more than 70 yrs 2)Peak Expiratory flow Rate less than 80 Lit/min are excluded 3)Asthma in pregnancy 4)Patients with severe attacks of Bronchial Asthma 5)Patients of Bronchial Asthma also suffering from other systemic disorders 6)The Bronchial asthma, associated with complications like emphysema and cor pulmonale. •

Design outcomes

Primary

Measure	Time frame
1) Relief in breathlessness 2) Relief in cough 3) Relief in wheezing 4) Reduced frequency of attacks of bronchial asthma 5) Reduced duration of attack of asthma 6) Increase in Peak expiratory flow rateTimepoint: 45th day	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactDr Ramakant Dwivedi

Shubhdeep ayurved medical college and hospital

doctoraksingh@yahoo.com9300681233

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026